Change in bone alkaline phosphatase as an outcome predictor in men with hormone-refractory prostate cancer metastasized to bone

Autor:	A. R. Allen, Jeffrey D. Isaacson, Fred Saad, D. J. Sleep, S. M. Hulting
Rok vydání:	2004
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Atrasentan medicine.disease Hormone refractory prostate cancer Prostate cancer Outcome predictor Internal medicine Medicine business Bone Alkaline Phosphatase medicine.drug
Zdroj:	Journal of Clinical Oncology. 22:4655-4655
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.4655
Popis:	4655 Background: Bone alkaline phosphatase (BAP) has been validated as a potential predictor of survival in hormone-refractory prostate cancer (HRPC) patients. Phase 2 results show that atrasentan,...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e8d5c0379ce2b2e530986560d1e32aaf https://doi.org/10.1200/jco.2004.22.90140.4655 Zobrazit plný text záznamu